According to the analysis of
Reports and Data, the global Acute
Respiratory Distress Syndrome Market was valued at USD 583.8
Million in 2018 and is expected to reach USD 934.8 Million by the year 2026, at
a CAGR of 6.0%. Acute respiratory distress syndrome (ARDS) is a type of
respiratory failure, which is a form of lung inflammation. Due to which there
is a problem with the proper delivery of the oxygen to the different body
organs, which at the end impact the appropriate functioning of the parts.
Various causes are included with the ARDS, such as sepsis, trauma, pneumonia,
and others. The primary treatment for the ARDS involves mechanical ventilation,
which is delivered through a rigid tube that enters the oral cavity and is
secured in the airway.
According to a survey done by the
World Health Organization (WHO), it is seen that more than 3 million people are
effects due to acute respiratory distress syndrome. It can affect people of all
ages. The main reason for the ARDS is air pollution, which is caused due to the
emission by the vehicles. The harmful gases emitted are inhaled by the people
thus leading to several problems.
Different strategic initiatives
have been undertaken by the various players in the ARDS industry. For instance,
on December 2018, Windtree Therapeutics, Inc. a biopharmaceutical company
merged with CVie Therapeutics and launched AEROSURF, a combination drug/device
product which is used to treat respiratory distress syndrome.
To identify the key trends in
the industry, click on the link below:
Further key findings from
the report suggest
- The market for acute respiratory distress syndrome is
anticipated to grow at a CAGR of 8.3% in the Asia-Pacific, followed by
North America and Europe, with 4.8% and 5.7% CAGR, respectively.
Increasing chronic diseases and the rise in air pollution are the key
factors to accelerate market growth during the forecast period across all
regions.
- As of 2018, the therapeutic device segment was valued
at USD 291.9 Million and is expected to grow at a CAGR of 5.8% during the
forecast period. Increasing preference for gastrointestinal bleeding and
pulmonary fibrosis has been one of the reasons for the growth of the acute
respiratory distress syndrome market.
- Due to the ARDS, various complications related to the
brain and lung are noticed. Neurological hypoxic brain damage is also one
of the injury types, which is reported for acute respiratory distress
syndrome.
- The treatment of acute respiratory distress syndrome
is Fibro Proliferate, resolution stage, recovery stage, and many more.
- The Asia-Pacific is the largest region for the acute
respiratory distress syndrome market due to the significant contribution
from countries like China, Japan, India, and Korea due to the growing
end-segment and sales channel industries.
- Asia Pacific region is accounted for the third
largest market share in 2017, due to consumption in well establishes and
end-user segment industries.
- Among the region, North America has the largest
market share. The primary driver for the acute respiratory distress
syndrome market in North America is the growing brain injury, thus owing
to the increase in injury type segment for the ARDS market.
- Key participants include Faron Pharmaceuticals,
BioMarck Pharmaceuticals, GE Healthcare, Hamilton Medical AG, Smiths
Medical, Athersys, GlaxoSmithKline, Altor Bioscience, and Mondobiotech.
Request for FREE PDF Sample Copy of This
Research Report at: https://www.reportsanddata.com/sample-enquiry-form/2089
For this report, Reports and Data
have segmented the acute respiratory distress syndrome market based on device
type, injury type, severity, treatment, sales channel, end user and region.
Device Type (Revenue in USD
Million; Volume in Tons, 2016–2026)
- Monitoring Devices
- Diagnostic Devices
- Blood Gas Analyzers
- Pulse Oximeters
- Spirometers
- Capnography Devices
- Other Diagnostic Devices
- Therapeutic Devices
- Mechanical Ventilators
- Invasive And Non-invasive Ventilators
- Drug Delivery Devices
- Nebulizers
- Humidifiers
- PAP
- Other Therapeutic Devices
Injury Type (Revenue in USD
Million; Volume in Tons, 2016–2026)
- Brain Injury
- Lung Injury
Severity (Revenue in USD
Million; Volume in Tons, 2016–2026)
- Mild
- Moderate
- Severe
Treatment (Revenue in USD
Million; Volume in Tons, 2016–2026)
- Fibro Proliferate
- Exudative Stage
- Resolution Stage
- Recovery Stage
Sales Channel (Revenue in USD
Million; Volume in Tons, 2016–2026)
- Direct Sales
- Channel Sales
End User (Revenue in USD
Million; Volume in Tons, 2016–2026)
- Hospitals
- Clinics
- Ambulatory Service Centers
- Other End Users
Regional Outlook (Revenue in
USD Million; Volume in Tons, 2016–2026)
- North America
- U.S
- Canada
- Europe
- Germany
- Italy
- U.K
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
- Rest of Latin America
Make an Inquiry of This Research Report at: https://www.reportsanddata.com/make-enquiry-form/2089
No comments:
Post a Comment